Eisai Co Ltd (ESALF) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

It is now time we would like to now begin the briefing session on the financial results and business update of ASI Company Limited. Today, we will be conducting the briefing session in hybrid format, including in-person attendance and online live streaming. For those of you who are attending in person, we have distributed consolidated financial reports, reference data, and financial results presentation. If you are attending online, please refer to these materials on our website. Let me now introduce the speakers today, Mr. Haruo Naito, Representative Corporate Officer and CEO, and Mr. Takuya Oyama, Vice President, CFO, and Chief IR Officer. First, Mr. Oyama, CFO, will present the financial results after which Mr. Naito, CEO, will report on the overall business. Mr. Oyama, CFO, please. Thank you very much for taking time out of your busy schedule to participate in this earnings call. Let me first share with you the financial highlights for fiscal year 2025. Next page. Revenue for fiscal year 2025 reached 825.4 billion yen, up 4.6% year-on-year. The pharmaceutical business, which is our organic business, delivered strong growth, driving consolidated revenue to a record high. Operating profit was 44.1 billion yen, down 18.8% year-on-year. Although there was a significant increase in the contribution of the pharmaceutical business to operating profit, OP declined due to factors such as decisions to forego product outlicensing or divestiture and the recognition of expenses related to structural reforms in Europe. For fiscal year 2026, we are projecting increased revenue and profit with revenue of 883.5 billion yen and operating profit of 70 billion yen. Regarding investments for growth, we have made two products in licensing investments to support further growth. Further...